CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of lymphomas and chronic lymphocytic leukemia (CLL).
  
  OVERVIEW OF ACTIVITY
  Hematologic cancers include the lymphomas, the leukemias, multiple myeloma and other related disorders stemming from lymphoid and myeloid progenitor cell lines. Taken together, it is estimated that approximately 176,200 new lymphoid, myeloid and leukemic cancer cases were identified in the United States in the year 2019, and 56,770 individuals died from these diseases. Importantly, more than 70 drug products are currently labeled for use in the management of hematologic cancers with more than 120 distinct FDA-approved indications. Although this extensive list of available treatment options is reassuring for patients and oncology healthcare professionals, it poses a challenge to the practicing clinician who must maintain up-to-date knowledge of their appropriate application across a vast spectrum of tumor types. This is particularly true for lymphomas and CLL, where the past several years have yielded a staggering number of important clinical and research advances.
  
  These proceedings from a CME symposium during the ASH Annual Meeting use the perspectives of a group of community oncologists/hematologists gathered during a daylong working group to establish and subsequently address some of the most frequently encountered questions and controversies facing clinicians involved in the management of these diseases. By providing information on the latest research developments and their potential application to routine practice, this activity is designed to assist hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of lymphomas and CLL with the formulation of up-to-date clinical management strategies.
  
  LEARNING OBJECTIVES
  

  • Review recent therapeutic advances and related FDA authorizations for newly diagnosed and relapsed/refractory mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and CLL, and use this information to counsel patients regarding protocol and off-protocol therapy.
  • Consider published Phase III efficacy and safety data evaluating the use of BTK inhibition as first-line therapy for patients with CLL, and use this information to discern how, if at all, these strategies can be optimally integrated into nonresearch care algorithms.
  • Recall the biologic rationale for, available research evidence with and ongoing research efforts evaluating the use of chemotherapy-free combinations for newly diagnosed and progressive FL, CLL and MCL to prepare for their potential introduction into the practical management of these diseases.
  • Develop an understanding of the biologic rationale for and appreciate available efficacy and safety data with chimeric antigen receptor T-cell therapy, and identify patients with relapsed/refractory B-cell lymphomas for whom this approach may be appropriate.
  • Describe available and emerging data with other investigational agents and immunotherapeutic strategies currently under evaluation for MCL, DLBCL, FL and CLL, and where applicable, refer eligible patients for trial participation.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THESE CME ACTIVITIES
  This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:
  
  Jeremy Abramson, MD
  Director, Center for Lymphoma
  Massachusetts General Hospital
  Associate Professor of Medicine
  Harvard Medical School
  Boston, Massachusetts
  
  Consulting Agreements: AbbVie Inc, Celgene Corporation, EMD Serono Inc, Genentech, Janssen Biotech Inc, Roche Laboratories Inc; Contracted Research: Celgene Corporation, Seattle Genetics.
  
  Bruce D Cheson, MD
  Frank M Ewing Foundation Chair in Hematology-Oncology
  Professor of Medicine
  Head of Hematology and Cellular Therapy
  Deputy Chief, Division of Hematology-Oncology
  Georgetown University Hospital
  Lombardi Comprehensive Cancer Center
  Washington, DC
  
  Advisory Committee: AbbVie Inc, Astellas, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Dr Reddy’s Laboratories Ltd, Epizyme, Genentech, Gilead Sciences Inc, Karyopharm Therapeutics, MorphoSys, Pharmacyclics LLC, an AbbVie Company, Roche Laboratories Inc, SymBio Pharmaceuticals Limited, TG Therapeutics Inc; Consulting Agreements: Astellas, Karyopharm Therapeutics, MorphoSys, Parexel International Corporation, SymBio Pharmaceuticals Limited; Contracted Research: AbbVie Inc, Adaptive Biotechnologies, Bristol-Myers Squibb Company, Celgene Corporation, Genentech, Gilead Sciences Inc, Pharmacyclics LLC, an AbbVie Company, Roche Laboratories Inc, Seattle Genetics, TG Therapeutics Inc, Trillium Therapeutics Inc.
  
  Prof John G Gribben, MD, DSc, FMedSci
  Chair of Medical Oncology
  Barts Cancer Institute
  Queen Mary University of London
  Charterhouse Square
  London, United Kingdom
  
  Advisory Committee: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Gilead Sciences Inc, Janssen Biotech Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Celgene Corporation, Janssen Biotech Inc; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP; Symposium Presentations: AbbVie Inc, Celgene Corporation, Gilead Sciences Inc, Janssen Biotech Inc, Roche Laboratories Inc.
  
  Brad S Kahl, MD
  Professor of Medicine
  Washington University School of Medicine
  Director, Lymphoma Program
  Siteman Cancer Center
  St Louis, Missouri
  
  Consulting Agreements: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, AstraZeneca Pharmaceuticals LP, BeiGene, Celgene Corporation, Genentech, Pharmacyclics LLC, an AbbVie Company, Roche Laboratories Inc.
  
  Loretta Nastoupil, MD
  Associate Professor
  Department of Lymphoma/Myeloma
  The University of Texas MD Anderson Cancer Center
  Houston, Texas
  
  Advisory Committee: Bayer HealthCare Pharmaceuticals, Celgene Corporation, Genentech, Gilead Sciences Inc, Janssen Biotech Inc, Juno Therapeutics, a Celgene Company, Novartis, Spectrum Pharmaceuticals Inc, TG Therapeutics Inc; Consulting Agreements: Celgene Corporation, Gilead Sciences Inc, Merck, Novartis; Contracted Research: Celgene Corporation, Genentech, Janssen Biotech Inc, Karus Therapeutics, LAM Therapeutics, Merck, TG Therapeutics Inc; Data and Safety Monitoring Board/Committee: Denovo Biopharma.
  
  Laurie H Sehn, MD, MPH
  Chair, Lymphoma Tumour Group
  BC Cancer Centre for Lymphoid Cancer
  Associate Editor, Blood
  Vancouver, Canada
  
  Consulting Agreements: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Amgen Inc, Apobiologix, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Genentech, Gilead Sciences Inc, Janssen Biotech Inc, Karyopharm Therapeutics, Kite Pharma Inc, Lundbeck, Merck, MorphoSys, Roche Laboratories Inc, Seattle Genetics, Takeda Oncology, Teva Oncology, TG Therapeutics Inc; Contracted Research: Genentech, Roche Laboratories Inc.
  
  CONSULTING ONCOLOGISTS/HEMATOLOGISTS — The following consulting oncologists/hematologists (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:
  
  Warren S Brenner, MD
  Lynn Cancer Institute
  Boca Raton, Florida
  
  Speakers Bureau: Celgene Corporation, Takeda Oncology.
  
  Gautam Kale, MD, MS
  Hematology (Lead) and Oncology Staff Physician
  Cone Health Cancer Center
  Greensboro, North Carolina
  
  No relevant conflicts of interest to disclose.
  
  Khuda Dad Khan, MD, PhD
  Hematology, Oncology, Immunology
  Norton Cancer Institute
  Norton Audubon Hospital
  Louisville, Kentucky
  
  Consulting Agreement: Novartis; Speakers Bureau: Alexion Pharmaceuticals, Genentech, Novartis.
  
  Zanetta S Lamar, MD
  Florida Cancer Specialists and Research Institute
  Naples, Florida
  
  No relevant conflicts of interest to disclose.
  
  Neil Morganstein, MD
  Hematology Oncology
  Atlantic Health System
  Summit, New Jersey
  
  No relevant conflicts of interest to disclose.
  
  Namrata I Peswani, MD
  Hematology Oncology/Palliative Care
  Advocate Medical Group
  Orland Park, Illinois
  
  No relevant conflicts of interest to disclose.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, Genmab, Genomic Health Inc, Gilead Sciences Inc, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Tolero Pharmaceuticals.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from AbbVie Inc, Adaptive Biotechnologies, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Genentech, Gilead Sciences Inc, Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC.
  
  Hardware/Software Requirements:
  A high-speed Internet connection
  A monitor set to 1280 x 1024 pixels or more
  Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
  Adobe Flash Player 27 plug-in or later
  Adobe Acrobat Reader
  (Optional) Sound card and speakers for audio
  
  Release date: February 2020
  Expiration date: February 2021